{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:32Z","timestamp":1792190612726,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073491"],"award-info":[{"award-number":["82073491"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.intimp.2023.110452","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:30:48Z","timestamp":1686270648000},"page":"110452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Immunosensitivity mediated by downregulated AKT1-SKP2 induces anti-PD-1-associated thyroid immune injury"],"prefix":"10.1016","volume":"121","author":[{"given":"Yanmeizhi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-1212","authenticated-orcid":false,"given":"Hong","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2023.110452_b0005","doi-asserted-by":"crossref","first-page":"e12731","DOI":"10.1111\/sji.12731","article-title":"Seminal immunologic discoveries with direct clinical implications: The 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy","volume":"88","author":"Ljunggren","year":"2018","journal-title":"Scand. J. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2023.110452_b0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"24","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"11","key":"10.1016\/j.intimp.2023.110452_b0015","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell Infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Can. Res."},{"issue":"13","key":"10.1016\/j.intimp.2023.110452_b0020","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"30","author":"Poto","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110452_b0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/imt-2018-0201","article-title":"Do immune-related adverse events correlate with response to immune checkpoint inhibitors?","volume":"11","author":"Saleh","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2023.110452_b0030","doi-asserted-by":"crossref","unstructured":"C.J. Voskens, S.M. Goldinger, C. Loquai, C. Robert, K.C. Kaehler, C. Berking, T. Bergmann, C.L. Bockmeyer, T. Eigentler, M. Fluck, C. Garbe, R. Gutzmer, S. Grabbe, A. Hauschild, R. Hein, G. Hundorfean, A. Justich, U. Keller, C. Klein, C. Mateus, P. Mohr, S. Paetzold, I. Satzger, D. Schadendorf, M. Schlaeppi, G. Schuler, B. Schuler-Thurner, U. Trefzer, J. Ulrich, J. Vaubel, R. von Moos, P. Weder, T. Wilhelm, D. G\u00f6ppner, R. Dummer, L.M. Heinzerling, The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network, PLoS One. 2013;8(1):e53745. 10.1371\/journal.pone.0053745. Epub 2013 Jan 14. PMID: 23341990; PMCID: PMC3544906.","DOI":"10.1371\/journal.pone.0053745"},{"issue":"5","key":"10.1016\/j.intimp.2023.110452_b0035","first-page":"1468","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Can. Sci."},{"key":"#cr-split#-10.1016\/j.intimp.2023.110452_b0040.1","doi-asserted-by":"crossref","unstructured":"Y. Xia, L. Jeffrey Medeiros, K.H. Young, Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies, Biochim Biophys Acta. 1865(1) (2016) 58-71. 10.1016\/j.bbcan.2015.09.002. Epub 2015 Oct 16. PMID: 26432723","DOI":"10.1016\/j.bbcan.2015.09.002"},{"key":"#cr-split#-10.1016\/j.intimp.2023.110452_b0040.2","doi-asserted-by":"crossref","unstructured":"Y. Xia, L. Jeffrey Medeiros, K.H. Young, Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies, Biochim Biophys Acta. 1865","DOI":"10.1016\/j.bbcan.2015.09.002"},{"key":"#cr-split#-10.1016\/j.intimp.2023.110452_b0040.3","unstructured":"(1) (2016) 58-71. 10.1016\/j.bbcan.2015.09.002. Epub 2015 Oct 16. PMID: 26432723; PMCID: PMC4733614."},{"issue":"1","key":"10.1016\/j.intimp.2023.110452_b0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","article-title":"Risk factors for immune-related adverse events: what have we learned and what lies ahead?","volume":"9","author":"Liu","year":"2021","journal-title":"Biomark Res."},{"key":"10.1016\/j.intimp.2023.110452_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115378","article-title":"Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma","volume":"208","author":"Yang","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"21","key":"10.1016\/j.intimp.2023.110452_b0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12575-019-0112-2","article-title":"Bone marrow-derived mesenchymal stem cells modified with akt1 ameliorates acute liver GVHD","volume":"16","author":"Zhou","year":"2019","journal-title":"Biol Proced Online."},{"issue":"5","key":"10.1016\/j.intimp.2023.110452_b0060","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ccell.2017.04.004","article-title":"Hippo signaling suppresses cell ploidy and tumorigenesis through Skp2","volume":"31","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.intimp.2023.110452_b0065","doi-asserted-by":"crossref","first-page":"e00592","DOI":"10.1128\/JVI.00592-18","article-title":"USP18 (UBP43) abrogates p21-mediated inhibition of HIV-1","volume":"92","author":"Osei Kuffour","year":"2018","journal-title":"J. Virol."},{"issue":"17","key":"10.1016\/j.intimp.2023.110452_b0070","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.1158\/0008-5472.CAN-09-1691","article-title":"Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis","volume":"69","author":"Saini","year":"2009","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.110452_b0075","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1038\/s41467-020-17395-y","article-title":"Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.110452_b0080","doi-asserted-by":"crossref","unstructured":"D. Wang, H. Qin, W. Du, Y.W. Shen, W.H. Lee, A.D. Riggs, C.P. Liu, Inhibition of S-phase kinase-associated protein 2 (Skp2) reprograms and converts diabetogenic T cells to Foxp3+ regulatory T cells, Proc. Natl. Acad. Sci. USA 2012 Jun 12;109(24):9493-8. 10.1073\/pnas.1207293109. Epub 2012 May 29. PMID: 22645357; PMCID: PMC3386130.","DOI":"10.1073\/pnas.1207293109"},{"key":"10.1016\/j.intimp.2023.110452_b0085","doi-asserted-by":"crossref","unstructured":"J. Liu, L. Quan, C. Zhang, A. Liu, D. Tong, J. Wang, Over-activated PD-1\/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen. Oncol Lett. 2018 Mar;15(3):3321-3328. 10.3892\/ol.2017.7682. Epub 2017 Dec 21. PMID: 29435074; PMCID: PMC5778856.","DOI":"10.3892\/ol.2017.7682"},{"issue":"5","key":"10.1016\/j.intimp.2023.110452_b0090","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/cncr.33270","article-title":"Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials","volume":"127","author":"Wang","year":"2021","journal-title":"Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923007750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923007750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:59:06Z","timestamp":1761587946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923007750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":20,"alternative-id":["S1567576923007750"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110452","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosensitivity mediated by downregulated AKT1-SKP2 induces anti-PD-1-associated thyroid immune injury","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110452"}}